News | February 12, 2008

Nfocus Neuromedical Receives CE Mark for the CardioVasc Stent-Graft, Delivery System

February 13, 2008 - Nfocus Neuromedical Inc. announced that the company has received CE mark approval for the CardioVasc Stent-Graft and Delivery System, a minimally invasive device for treating patients with Saphenous Vein Graft Lesions (SVGs) from a previous coronary bypass, Vessel Perforations and Coronary Artery Aneurysms.

Saphenous vein graft (SVG) disease has been a problem facing the cardiologist since the early days of coronary artery bypass graft (CABG) surgery said the company. In CABG surgery, a segment of the patient's own leg vein (the saphenous vein) may be removed and used to create an artificial conduit to bypass areas of blood flow blockage (also known as stenosis or plaque) that have built up in the patient's coronary artery. After CABG surgery, this SVG bypass itself may become blocked over time by the same type of disease that affected the patient's original coronary artery. The result is a need to reopen the diseased SVG vessel and restore flow. This second treatment again can be yet another surgery, or alternatively, the SVG may be treated via angioplasty and stenting procedures using less invasive endovascular (catheter) techniques. The CardioVasc Stent-Graft device is a permanent implant delivered via a less-invasive catheter procedure for patients that have a diseased SVG from a previous CABG surgery.

For more information: www.nfocusneuro.com

Related Content

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent. #TCT2018

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent.

News | Stents | October 04, 2018
October 4, 2018 – Investigators unveiled clinical data from the independent BIONYX and SORT OUT IX all-comers trials
FDA Approves Biotronik's PK Papyrus Stent for Coronary Perforations
Technology | Stents | September 27, 2018
September 27, 2018 — Biotronik recently announced U.S.
Videos | Stents | September 11, 2018
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init